novartis-tafasitamab
PreclinicalMonoclonal antibody
Novartisnovartis-tafasitamab is one of 60 therapeutic programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
59
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
109 competitors in Diffuse Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Rituxan
RochePhase 3
Oncovin
Eli LillyPhase 3
Polivy
RochePhase 3
Adriamycin
PfizerPhase 3
Gemzar
Johnson & JohnsonPhase 3
Gazyva
RochePhase 3
Oncovin
Eli LillyPhase 3
Rayos
RRoxane Laboratories
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for novartis-tafasitamab. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody
- Highest Phase
- Preclinical
- Company